Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies Who Have Undergone Donor Stem Cell Transplant

Inclusion Criteria

• Lack of suitable conventional donor (i.e. 5/6 or 6/6 related or 5/6 or 6/6 unrelated donor) or presence of a rapidly progressive disease not permitting time to identify an unrelated donor
• Patients with acute lymphoblastic leukemia (ALL) or high grade (stage III or IV) non-Hodgkin lymphoma (NHL) after first relapse or with primary refractory disease
• Myelodysplastic syndrome
• Acute myeloid leukemia (AML) after first relapse or with primary refractory disease
• Chronic myelogenous leukemia (CML)
• Hemophagocytic lymphohistiocytosis (HLH), familial hemophagocytic lymphohistiocytosis (FLH), viral-associated hemophagocytic syndrome (VAHS), X-linked lymphoproliferative disease (XLP), severe chronic active Epstein Barr virus infection (SCAEBV) with predilection for T- or natural killer (NK)-cell malignancy
• Donor cells should be collected and frozen before conditioning starts

Exclusion Criteria

• Patients with a life expectancy (=< 6 weeks) limited by diseases other than leukemia
• Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by echocardiogram (i.e., shortening fraction < 25%)
• Patients with severe renal disease (i.e., creatinine clearance less than 40 cc/1.73 m^2)
• Patients with pre-existing severe restrictive pulmonary disease (forced vital capacity [FVC] less than 40% of predicted)
• Patients with severe hepatic disease (direct bilirubin greater than 3 ug/dl or serum glutamic pyruvate transaminase [SGPT] greater than 500 ug/dl)
• Patients with severe personality disorder or mental illness that would preclude compliance with the study
• Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation
• Patients with documented human immunodeficiency virus (HIV) positivity